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Background: Research antibodies are used by thousands of scientists working in diverse disciplines, but it is common
to hear concerns about antibody quality. This means that researchers need to carefully choose the antibodies they use
to avoid wasting time and money. A well accepted way of selecting a research antibody is to identify one which has
been used previously, where the associated data has been peer-reviewed and the results published.
Description: CiteAb is a searchable database which ranks antibodies by the number of times they have been cited. This
allows researchers to easily find antibodies that have been used in peer-reviewed publications and the accompanying
citations are listed, so users can check the data contained within the publications. This makes CiteAb a useful resource
for identifying antibodies for experiments and also for finding information to demonstrate antibody validation. The
database currently contains 1,400,000 antibodies which are from 90 suppliers, including 87 commercial companies and
3 academic resources. Associated with these antibodies are 140,000 publications which provide 306,000 antibody
citations. In addition to searching, users can also browse through the antibodies and add their own publications to the
CiteAb database.
Conclusions: CiteAb provides a new way for researchers to find research antibodies that have been used successfully in
peer-reviewed publications. It aims to assist these researchers and will hopefully help promote progress in many areas
of life science research.
Keywords: Antibodies, Monoclonal, Polyclonal, Western blotting, Flow cytometry, Immunohistochemistry, ChIP host
species, Species reactivity, CitationsBackground
Research antibodies are used by life scientists who work
in areas ranging from cell biology to immunology and
from neuroscience to cancer research. The sheer scale of
their use is illustrated by the fact that the market for
commercial research antibodies is estimated to be over
$1.6 billion annually [1]. However, there are often com-
plaints from researchers about antibody quality [2-4] and
new researchers learn that it is important to find well vali-
dated antibodies or risk wasting money and perhaps more
importantly, time [5]. The selection of an antibody is* Correspondence: ac270@bath.ac.uk
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stated.complicated by the fact that they are used for a wide
variety of applications, including western blotting, flow
cytometry, ELISA, immunoprecipitation, chromatin im-
munoprecipitation (ChIP) and immunohistochemistry
[6-9] and suitability for one application is not a guaran-
tee of good performance with another application. In
addition, antibodies are often used against an antigen
from a different species to the one that the antibody was
raised against: meaning that the amount of cross species
reactivity shown by the antibody needs to be considered.
Many researchers would agree that the most reliable
way of overcoming these issues and identifying a suit-
able antibody would be to find one that has already been
used for the application/species required and the results
published in one or more publications.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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antibodies by the number of times they have been cited
in peer-reviewed journal articles, making it easy to find
antibodies that have been successfully used. This approach
to finding antibodies has advantages over a Google search,
which is dependent on many factors which do not directly
relate to antibody quality. For example, the supplier with
the best search engine optimisation does not necessarily
provide the most suitable antibody. There are existing spe-
cialist databases which rank antibodies based on commer-
cial criteria and there are also others which help scientists
find independently validated antibodies by collecting user
reviews. CiteAb takes an alternative approach and focuses
entirely on using peer-reviewed publications as a guide to
the level of independent validation. Ranking by citations
provides a simple and transparent method of helping re-
searchers find an antibody that has been independently
validated for a particular experimental method and/or
species of interest. A citation means that the antibody has
generated data worthy of publication in a peer-reviewed
journal, which in our opinion provides the best guide
when selecting an antibody. Having identified a potential
antibody of interest, researchers can then link to the listed
scientific papers and establish how the antibody has been
used and examine the data contained within the publica-
tions. In addition to search, the key features of CiteAb in-
clude the ability to browse for antibodies of interest and
for users to improve the database by adding information
on their own publications if they are not already included.
This article will provide an overview of the data currently
stored in the CiteAb database, the different ways users can
interact with it and finally a comparison of the results ob-
tained from a range of different antibody search engines.
Construction and content
CiteAb has a simple database architecture consisting of an
entry with associated data fields for each antibody and pub-
lication. The antibody pages are searchable and linked to
the relevant publication pages (the user workflow is de-
scribed below). To maximise CiteAb’s utility for researchers
as many antibodies as possible are listed and antibodies
from any commercial company or academic resource can
be included. Current statistics (December 2013) show that
CiteAb contains 1,400,000 antibodies from 90 suppliers.
These suppliers include 87 commercial companies and 3
academic resources. The academic resources are normally
grant funded or non-profit self-funded centres and cur-
rently include the Developmental Studies Hybridoma Bank
(DSHB) based at the University of Iowa, NeuroMab based
at the University of California Davis and the Zebrafish
International Resource Centre (ZIRC) from the University
of Oregon, which works closely with the Zebrafish Model
Organism Database (ZFIN) [10]. These resources are all
currently funded, or were funded, by the National Instituteof Health (NIH). For example the DSHB was funded by the
NIH, but is now self-funded. More recently we have tried
to encourage individual academics to list their antibodies
and created a special category ‘academic antibodies (indi-
vidual labs)’ to facilitate this. For this type of listing we ask
that the academic be willing to distribute their antibody on
request.
The second data type required to maximise the useful-
ness of CiteAb is to link as many publications as possible
to these antibodies. CiteAb currently (December 2013)
contains 140,000 publications, which provide 306,000 anti-
body citations. Despite the importance of citations, CiteAb
does list antibodies which currently lack them. This is be-
cause newly released antibodies will not have citations, but
are still likely to be of interest to users. In addition having
these antibodies listed makes it easier for users to add cit-
ation data to them.
The data in CiteAb is obtained from multiple sources
including the suppliers, academic resources, from users
adding information on the antibodies they have used
(discussed below) and from our curation of antibodies
and citations. Different approaches to data collection are
used as no single method can identify all the publica-
tions that use antibodies, and establish the application
and species used within the publications. An example of
using a particular data source is the information kindly
provided by Xenbase [11], whose data lists publications
where antibodies were used with the model organism
Xenopus. Quality control for the information obtained
from the different data sources is ensured using two com-
plementary mechanisms. Data is batch tested to ensure it is
reliable and prominent “report a problem” buttons are dis-
played on the antibody pages so users can report any errors
that do make it into the database. The ability to check the
source data is a key advantage of using citations as a guide
to the likely suitability of an antibody. The amount of data
contained within CiteAb has grown rapidly since the
launch of the trial site in September 2012 (Table 1 and our
statistics page (blog.citeab.com/citeab-database-statistics)
and our most important future goal is to continue to in-
crease the number of antibodies and publications which are
contained within the database.
Utility and discussion
Searching CiteAb for antibodies
The main way for users of CiteAb to access information
is via the search function. This feature can be accessed
from any page and requires researchers to input a search
term in the prominent search box (www.citeab.com/).
Fields for the antibody name, supplier code, clone num-
ber, synonym and immunogen for each antibody within
the CiteAb database are then searched for the entered term.
The antibodies returned by a search are ranked by the
number of times they have been cited and are presented in
Table 1 Growth of the CiteAb database












Trial site launched 1/9/12 400,000 35 1 - 35,000 -
Version 1 launched 11/3/13 900,000 51 3 - 115,000 237,000
Addition of extra antibody
information fields
5/8/13 1,125,000 72 3 1 123,000 260,000
Resubmission of the
CiteAb paper
11/12/13 1,400,000 87 3 1 140,000 306,000
The table shows how the amount of antibody and citation data that is included in CiteAb has increased over time. Current information can be viewed on our
statistics page (blog.citeab.com/citeab-database-statistics).
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This information includes; the antibody name (blue text),
antibody code (under antibody name), name of the supplier
who provides the antibody, host species, applications, spe-
cies reactivity and number of citations. The information on
applications and species reactivity includes data from peer-
reviewed publications (red text) and recommendations pro-
vided by the supplier (black text). The search results can be
filtered by the following features; the supplier, host species,
experimental application, species reactivity, conjugate and
clonality.
Having identified an antibody of interest, users are
then able to navigate to the ‘antibody page’ (Figure 2) by
clicking on the relevant row for the antibody. An anti-
body page displays the antibody code, antibody name,
name of the supplier, host species, published applications
and published species reactivity. A recent upgrade of the
database has added fields for the following; whether the
antibody is polyclonal or monoclonal, clone number if
monoclonal, any conjugated moiety such as Fluorescein
isothiocyanate (FITC), synonyms for the target protein and
information on the immunogen. These fields are only dis-
played if the information is present in the database, for the
example shown in Figure 2 fields for synonym, clone num-
ber and conjugated moiety are not displayed. Fields for
supplier recommended applications and supplier recom-
mended species reactivity have also recently been added.
Uploading of information for the new fields is ongoing, so
not all antibodies will have this additional information. If
the antibody appears worthy of further investigation the
user can follow links to the corresponding antibody page
on the supplier website for further information.
The antibody pages have a ‘Report a Problem’ button,
enabling users to highlight any errors in the information
displayed and an ‘Add a Publication’ button which allows
users to add information on their own publications if they
are not already contained within CiteAb (see below). They
also list the publications that have cited the antibody and
each publication has a link to a corresponding ‘publication
page’. The publication pages (Figure 3) give information on
each publication, including article title, abstract, authors,
journal and a list of the antibodies cited in the publication.This page also includes links to the relevant entry in
PubMed and to the publishing journal’s page for the article.
The publication metadata is provided under licence by
PubMed [12] a database of the U.S. National Library of
Medicine.
Browsing antibodies in CiteAb
The second way in which users are able to access infor-
mation in CiteAb is via a browse function (www.citeab.
com/browse/companies). This allows users to browse for
antibodies of interest via the supplier, the host species,
the application or the species reactivity. Having selected
a feature to browse by, for example ‘applications’, an alpha-
betical list of available applications is displayed (Figure 4A).
Selecting a specific application, such as ChIP, then returns
a list of antibodies that are potentially suitable for this
application (Figure 4B). The user is then able to browse
through these antibodies or add additional filters or search
terms, to identify specific antibodies of interest.
The browsing options do not include an alphabetical
list of antibodies because antibody names do not follow
a consistent format. For example, a polyclonal goat anti-
p53 antibody might be named anti-p53 polyclonal anti-
body, goat anti-p53 polyclonal antibody, p53 polyclonal
antibody or polyclonal anti-p53 antibody. This variation,
combined with the large numbers of antibodies in many
categories, makes alphabetical browsing potentially mis-
leading and in our opinion of little value.
Users can add their publications to CiteAb
A third way in which users can interact with CiteAb is to
add information on the antibodies used in their publica-
tions if they are not already contained within the database
(www.citeab.com/suggest_publication). This is carried out
using a three step submission process. First, the user en-
ters the PubMed ID of their paper and confirms it is cor-
rectly identified (Figure 5). They then select an antibody
used in the publication by its code number (Figure 6A)
and information on the application and species reactivity
for the antibody can be added (Figure 6B). The second
two steps are repeated for each antibody used in the publi-
cation, before the information is reviewed and submitted.
Figure 1 A CiteAb search results page. The antibodies returned by a search are displayed in a table and ranked by the number of times they
have been cited (far right column). The following antibody information is displayed; the antibody name (blue text), antibody code (below the
name), name of the supplier, host species and information on applications and species reactivity. Application and reactivity data includes supplier
recommendations (black text) and data from peer-reviewed publications (red text). Filters (far left hand side) are available for the supplier, host
species, application, species reactivity, conjugate and clonality.
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Figure 2 Example of a CiteAb antibody page. Each antibody page provides details of the antibody code, antibody name, name of the
supplier, host species, whether the antibody is polyclonal or monoclonal, clone number if monoclonal (not present in this example), any
conjugated moiety such as FITC (not present in this example), synonyms for the antigen (not present in this example) and information on the
immunogen. Published reactivity, published applications, supplier recommended reactivity and supplier recommended applications are also
provided where available. Not all antibodies will have complete information as several of these data fields have been added recently and
uploading of the additional information is continuing. The antibody page also lists publications that have cited the antibody. The first ten are
shown automatically, with an option to view the remainder. Each publication has a link to a corresponding ‘publication page’ (Figure 3). There
are also links to add a publication, report a problem and sign up to the CiteAb newsletter.
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enter detailed publication or antibody information in
order to make the process as quick and simple as possible
and to hopefully reduce data entry errors.
If an antibody used in the publication is not currently
listed in CiteAb, then a new antibody can be added to
the database. In this case the user is asked for key infor-
mation regarding the antibody including the supplier ofthe antibody, antibody name, antibody code number and
host species. This allows researchers to add any antibody
they have used, including those they have raised in their
own laboratories.
We try and encourage our users to add information
on their publications as the more researchers that add
citations to CiteAb the greater its use will be to the sci-
entific community. Users who add their citations may
Figure 3 A CiteAb publication page. The publication pages display the article title, abstract, authors, journal and a list of the antibodies cited in
the publication. This page also includes links to the relevant entry in PubMed and to the publishing journal’s article page. The publication
metadata is provided under license by PubMed [12].
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researchers who are using the site, potentially increasing
the impact of their publications.
Other features
The ‘About Us’ section (www.citeab.com/about) provides
users with information regarding how the CiteAb anti-
body search engine functions, the people who work onthe CiteAb database and how to list antibodies. It also
has links to a help page, a database statistics page, an ac-
knowledgement page and a page providing further ad-
vice on listing antibodies. There is a prominent ‘Contact’
page (www.citeab.com/contact) enabling users to ask for
additional information if required. CiteAb also has a
Blog (blog.citeab.com/) and a newsletter (www.citeab.com/
newsletter) which are designed to provide information on
AB
Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Browsing antibodies in CiteAb. (A) Selecting a feature to browse by, for example ‘applications’ (upward arrow), returns an
alphabetical list of available applications. (B) Selecting a specific application, such as ‘Chromatin Immunoprecipitation’ (blue box), then returns a
list of antibodies that may be suitable for this application. This data includes applications recommended by the suppliers and applications from
publications. Users can add further filters and search terms as required.
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journal/publishing features that may be of interest to users.
A useful source of information regarding antibody validation
CiteAb is designed to help researchers find antibodies
for their research. However, it has another use which is
as a source of information regarding antibody validation.
The Nature Publishing Group have recently introducedFigure 5 Adding publication information to CiteAb (Step 1). A three s
step one a user enters the PubMed ID of a publication and confirms it is ca reporting checklist for articles [13], which highlights
the fact that reporting of research antibodies in publica-
tions needs to be improved and we have subsequently
suggested a standardised format [14]. One of the recom-
mendations from the checklist, and our article, is that
authors need to show that the antibodies they use have
been properly validated. Antibody validation is a com-
plicated topic [15-19], but one way of demonstratingtep submission process is used to enter publication information. In
orrectly identified. Figure 6 illustrates steps two and three.
AB
Figure 6 Adding publication information to CiteAb (Steps 2 + 3). A three step submission process is used to enter publication information.
(A) In step two an antibody used in the publication is selected by entering its code number and selecting the relevant antibody. (B) In step
three, information on the application and species reactivity for the antibody is added. Steps two and three are repeated for each antibody used
in the publication and the information is then reviewed and submitted. Figure 5 illustrates step one of the submission process.
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Table 2 Search results from a range of antibody search engines
Antibody search engine CD4 for flow cytometry GAPDH for Western blotting STMN3
1DegreeBio (www.1degreebio.org) BioLegend (100405) Abcam (ab9485) Atlas Antibodies (HPA012947)
Antibody Directory (www.antibodydirectory.com) Cell Sciences (MON2067) LabFrontier Life Science Institute (LF-PA0006) None
Antibody Registry (www.antibodyregistry.org) GeneTex (GTX21089) MBL International (JM-3777-100) LifeSpan BioSciences (LS-C39280-50)
Antibody Resource (www.antibodyresource.com) SICGEN (AB0091-200) SICGEN (AB0067-200) Abbexa (abx14926)
Antibody Review (www.antibodyreview.com) LifeSpan Biosciences (LS-C21574) Creative Biomart (CPBT-53909RH) None
Antibodypedia (www.antibodypedia.com) Novus Biologicals (NBP1-19371) Proteintech (10494-1-AP Atlas Antibodies (HPA012947)
Benchwise (www.benchwise.org) BD Biosciences (552775) Abcam (ab8245) None
BioBrea (www.biobrea.com) BD Biosciences (550280) Abcam (ab8245) Proteintech (11311-1-AP)
Biocompare (www.biocompare.com) Antibodies-online (ABIN641732) Antibodies-online (ABIN569034) Biorbyt (orb31054)
CiteAb (www.citeab.com) AbD Serotec (MCA1749) Santa Cruz Biotechnology (SC-25778) Proteintech (11311-1-AP)
Labome (www.labome.com) LifeSpan Biosciences (LS-B3426) Abbiotec (252626) Santa Cruz Biotechnology (SC-85907)
Linscott Directory (www.linscottsdirectory.com) BACHEM AMERICAS (T-1364.0100) Synaptic Systems (247 002) Proteintech (11311-1-AP)
pAbmAbs (www. pabmabs.com) None Sigma (G8795) None
Scrazzl (www.scrazzl.com) Santa Cruz Biotechnology (sc-19642) Abcam (ab83957) Abcam (ab76678)
Three searches were carried out with a range of antibody search engines and the top ranked antibody recorded. The first two searches were for commonly used antibodies (CD4/filter flow cytometry) and (GPDH/filter
Western blotting). The third is a less common search (STMN3) which was randomly selected (it was the 100th most common search in CiteAb in the preceding three months). Results from CiteAb are highlighted in
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previously validated. Another is to cite the antibody page
from a database that provides evidence of past use. In
both these cases CiteAb can help researchers show anti-
body validation.
Comparison with the results from other antibody
search engines
The task of selecting an antibody is far from straightfor-
ward and, as mentioned above, several existing antibody
search engines have been developed to help this process.
The way search engines rank antibodies falls into three
rough categories. Some use a commercial model where
suppliers pay to be top ranked while others use user re-
views to provide independent validation and a method
of ranking. In contrast CiteAb uses citations for inde-
pendent validation and ranking. A search engine called
BioBrea also uses a similar approach and ranks by cita-
tions. Search engines may also mix different models by
allowing suppliers to pay to be top ranked/highlighted,
but rank the remainder of the antibodies by reviews or
citations. The different approaches have different advan-
tages and disadvantages. User reviews can provide valu-
able independent information regarding validation of the
antibody, but they can be hard to collect and it may be
difficult to assess the validity of the review. Citations are
independent and Citeab displays them so users can check
the data contained within the papers. However, citations
may take time to appear for new antibodies. The paid
models allow companies to promote new antibodies which
will initially lack citations and reviews but may be the best
available product.
To allow a comparison of the results obtained from
different antibody search engines 14 of them were tested
with three search terms (Table 2). Two search terms
are for commonly used antibodies (1, search CD4 and
filter for flow cytometry. 2, search GAPDH and filter
for Western blotting) and the third was less widely used
(search STMN3). The striking thing about the results is
the variety of antibodies that were returned as the top hit
by the different search engines (Table 2). There is almost
no overlap in the results which are returned. It is not pos-
sible to say which is the “best” antibody search engine
from this analysis. The results from each search would
need to be experimentally tested in an independent la-
boratory. However, it does demonstrate how challenging it
is to select an antibody to buy. Our opinion is it is advis-
able for researchers to use multiple search engines, look
into the data behind the results and consider several anti-
bodies if available. This allows an informed decision to be
made. It is also important to stress that once purchased
the antibody should still be validated for the application
and species being used within the purchasing lab. This in-
formation, along with validation of new antibodies, canthen be included as part of future publications to help
other researchers.
Future directions
Our major future goal is to continue to improve the
quantity and quality of the antibody and citation data
contained within the CiteAb database. In terms of tech-
nical improvements, we want to improve the ability of
users to browse and filter publications that are associ-
ated with an antibody. In the longer term the database is
also likely to adapt to accommodate changes in available
antibodies, such as increasing numbers of recombinant
antibodies and also adding other types of affinity re-
agents. There is no doubt that there are other improve-
ments that could be made to CiteAb and we would
appreciate any suggestions from readers of this article.
Conclusions
The goal of CiteAb is to help researchers succeed by
making it easier for them to find the right research anti-
body for their experiments. It does this by ranking re-
search antibodies by the number of times they have been
cited and making it easy for researchers to explore the
citations. This database will hopefully save scientists time
and money and by doing this help life science research
progress more rapidly. Our initial feedback has been that
researchers find CiteAb a useful resource and our analyt-
ics data shows that we have increasing numbers of repeat
visitors. Our aim is to continue to improve CiteAb and
make it as valuable to researchers as possible.
Availability and requirements
The CiteAb database can be accessed at www.citeab.
com. It is freely available for use by academics and non-
academics without the need for login or registration.
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